Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.66 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 13/20 | 0.65 |
| ▸ | RAB9A | P51151 | 13/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.62 |
| ▸ | RELA | Q04206 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6015198 | 0.84 | NPC1 (0.83) | KDM4ENOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL120253 | 0.84 | NPC1 (0.83) | KDM4ENOTUMNPC1RAB9ASMN1; SMN2 | |
| Hydrazinecarboxamide SCHEMBL22471907 | 0.84 | KDM4E (0.71) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL3173832 | 0.83 | NPC1 (0.79) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL26673871 | 0.83 | NPC1 (0.78) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL13231671 | 0.82 | NPC1 (0.79) | KDM4ENOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10103078 | 0.80 | KDM4E (0.66) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL15718167 | 0.79 | DGAT1 (1.00) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL20767009 | 0.79 | NPC1 (0.72) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL12550898 | 0.79 | KDM4E (0.66) | KDM4ENOTUMDGAT1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515801-A | AIE fluorescent nano probe and preparation method thereof | 苏州工业园区服务外包职业学院(苏州市服务外包人才培养实训中心) | 2024-08-20 | — | — | CN | disclosed |
| WO-2023225327-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | KUDA Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| CN-110878106-B | Preparation method of Mannich base containing ferrocenyl thiadiazole or oxadiazolyl | 陕西科技大学 | 2022-05-03 | — | — | CN | disclosed |
| CN-109438433-B | Myricetin derivative containing amide oxadiazole, preparation method and application thereof | 贵州大学 | 2022-02-15 | — | — | CN | disclosed |
| CN-110627783-B | Preparation method of Schiff base containing carbazolyl and oxadiazolyl or thiadiazolyl | 陕西科技大学 | 2021-11-16 | — | — | CN | disclosed |
| WO-2020219287-A1 | CAMPTOTHECIN DERIVATIVES | IMMUNOGEN, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| CN-110878106-A | Preparation method of Mannich base containing ferrocenyl thiadiazole or oxadiazolyl | 陕西科技大学 | 2020-03-13 | — | — | CN | disclosed |
| CN-107216357-B | Preparation method of Mannich base containing ferrocenyl oxadiazolyl | 陕西科技大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-110759955-A | Preparation method of Mannich base containing ferrocenyl thiadiazole or oxadiazolyl | 陕西科技大学 | 2020-02-07 | — | — | CN | disclosed |
| CN-110627783-A | Preparation method of Schiff base containing carbazolyl and oxadiazolyl or thiadiazolyl | 陕西科技大学 | 2019-12-31 | — | — | CN | disclosed |
| CN-109438433-A | A kind of myricetin derivative, the preparation method and the usage of amide containing oxadiazoles | 贵州大学 | 2019-03-08 | — | — | CN | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| WO-2011029027-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | HIF1AN, HIF1A, EGLN2 | KDM4E 686/4885NOTUM 4790/4885DGAT1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.